Drugmaker AbbVie has agreed to license a weight-loss drug currently in development from Gubra for up to about $2.2 billion, marking its entry into the obesity treatment market.
During a hearing, representatives for the Newsom administration said they could not provide a timeline for when ...
Some results have been hidden because they may be inaccessible to you
Show inaccessible results
Feedback